Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 230,930
  • Shares Outstanding, K 101,285
  • Annual Sales, $ 0 K
  • Annual Income, $ -82,180 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.77
Trade CMPX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.11
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.16
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +25.97%
on 09/26/22
3.67 -37.87%
on 09/14/22
-0.71 (-23.75%)
since 08/30/22
3-Month
1.81 +25.97%
on 09/26/22
3.67 -37.87%
on 09/14/22
-0.37 (-13.96%)
since 06/30/22
52-Week
1.25 +82.40%
on 03/29/22
4.38 -47.95%
on 11/02/21
-1.13 (-33.14%)
since 09/30/21

Most Recent Stories

More News
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A...

CMPX : 2.28 (+2.70%)
5 Oncology Stocks Wall Street Predicts Will Rally 135% or More

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and...

CMPX : 2.28 (+2.70%)
CRDF : 1.5400 (unch)
ELEV : 1.1300 (-3.42%)
GH : 53.83 (+0.20%)
SURF : 1.0400 (-2.80%)
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary...

CMPX : 2.28 (+2.70%)
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase...

CMPX : 2.28 (+2.70%)
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass...

CMPX : 2.28 (+2.70%)
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing...

CMPX : 2.28 (+2.70%)
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing...

CMPX : 2.28 (+2.70%)
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced...

CMPX : 2.28 (+2.70%)
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary...

CMPX : 2.28 (+2.70%)
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D.,...

CMPX : 2.28 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.48
1st Resistance Point 2.38
Last Price 2.28
1st Support Level 2.19
2nd Support Level 2.10
3rd Support Level 2.00

See More

52-Week High 4.38
Fibonacci 61.8% 3.18
Fibonacci 50% 2.82
Fibonacci 38.2% 2.45
Last Price 2.28
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar